News – Page 1152 – Endpoints News

Alexion CEO, CFO make a sudden exit as internal fraud probe explodes into a crisis

9 years ago

Gates-backed Exicure wraps 2016 with its first major collaboration and a plan for the year ahead

9 years ago

Achaogen slowly soars, speeding top antibiotic to FDA/EMA after PhIII scores positive results

9 years ago

Novartis-allied Ophthotech blitzed after a pair of PhIII disasters for wet-AMD franchise drug

9 years ago

Your attention, please: AstraZeneca asks for a moment of rapt silence, for a BLA acceptance?

9 years ago

Synergy outlines upbeat PhIII data; Bluebird and Blueprint raising $375M

9 years ago

Thinking big, Bayer’s Axel Bouchon tackles stem cell field with $225M startup partnered with Versant

9 years ago

Drug pricing remains the big issue for 2017; Let's not go down the rabbit hole at the FDA

9 years ago

Moving on past sola wreckage, Lilly doubles down on one more Alzheimer’s drug from AstraZeneca

9 years ago

Eli Lilly conducts an autopsy of an Alzheimer’s megaflop

9 years ago

Biogen spells out remarkable efficacy data in Alzheimer's for aducanumab, but safety threat persists

9 years ago

Virtual biotech star Mark de Souza signs up to help lead the team on a new co launch; Takeda partners with RNA ...

9 years ago

The 21st Century Cures Act is here to stay. Now what?

9 years ago

Gilead offers rare apology to payers over the hep C drug sticker shock

9 years ago

Horizon Pharma folds its cards on Friedreich’s Ataxia after Actimmune flunks PhIII

9 years ago

MPM kicks off a new I/O player with $44.5M round and a new understanding of the T cell receptor

9 years ago

Seasteader, drug libertarian and now FDA Commissioner? Peter Thiel backs a radical shift

9 years ago

Voyager shares spike on an early glimpse of promise for Parkinson’s gene therapy

9 years ago

Ariad’s brigatinib scores 15.6 month PFS rate; Neurimmune backs ALS spinout

9 years ago

J&J is forced to suspend recruitment in PhI diabetes study, raising questions about another Hanmi drug

9 years ago

AbbVie’s PARP inhibitor flounders in PhII as rivals surge ahead in late-stage drive

9 years ago

PEOTUS Donald Trump vows to rein in drug prices, slamming biotech stocks

9 years ago

Sayonara Novartis: Ex-cell therapy chief challenges CAR-T leaders, moves to Carl June’s biotech startup

9 years ago

With new name, new CEO, Cascadian now rolls out a new pivotal plan for lead cancer drug

9 years ago

First page Previous page 1149 1150 115111521153 1154 1155 Next page Last page